TCL Archive NCI Program Review: Report calls For Two Types Of Centers: Comprehensive And All Others October 18, 1996
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive DCPC Board Approves Concepts for $28.5 Million Polyp Trial, Other Nutrition Related Studies May 19, 1989
